Neurocrine biosciences leverages picnichealth to reveal critical care gaps for patients with rare genetic condition

Technology-enabled research approach and ai-powered analysis identify unmet needs in patients with congenital adrenal hyperplasia san francisco , july 15, 2025 /prnewswire/ -- picnichealth , a health technology company dedicated to advancing the next generation of non-interventional research, today announced its research collaboration with neurocrine biosciences, inc. (nasdaq: nbix), the cahtalog® registry, identified an unmet need in patients with classic congenital adrenal hyperplasia (cah). using picnichealth's ai-powered technology to curate medical records and enable remote participation, the study revealed that cah patients require lifelong, continuous adjustments to glucocorticoid dosing—the current standard treatment—to maintain condition control.
NBIX Ratings Summary
NBIX Quant Ranking